A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-02-10
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial
to evaluate the efficacy and safety of Fruquintinib plus best supportive care in patients
with advanced non-squamous non-small cell lung cancer who failed to second-line standard
chemotherapy.